Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Qiagen NV    QGEN   NL0000240000

QIAGEN NV (QGEN)

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

QIAGEN NV : Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Second Quarter 2010 Financial Results Call Set for August 10

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/03/2010 | 02:05pm CEST

VENLO, The Netherlands, Aug. 3 /PRNewswire-FirstCall/ -- QIAGEN N.V. (Nasdaq: QGEN) today announced the Webcast of its second quarter 2010 financial results call. The Webcast will take place at 9:30 a.m. EDT on Tuesday, August 10, and will include remarks by Peer M. Schatz, President and Chief Executive Officer, and Roland Sackers, Chief Financial Officer.


                    Webcast of QIAGEN's second quarter 2010 financial
    What:            results call

    When:           9:30 a.m. EDT on August 10

                    The Webcast is accessible at www.qiagen.com/goto/
    Where:           ConferenceCall

    How:            Log on to the Web at the address above

                    The corresponding presentation slides will be
                    available for download in the investor relations
                    section of QIAGEN's Web site at www.qiagen.com/
                    goto/ConferenceCall.

                    Andreas Marathovouniotis, Russo Partners, (212)
    Contact:        845-4235

QIAGEN N.V., a Netherlands holding company, is the leading provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 consumable products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include what is considered to be the broadest panel of molecular diagnostic tests available worldwide. This panel includes the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer.

QIAGEN employs more than 3,500 people in over 30 locations worldwide. Further information about QIAGEN can be found at www.qiagen.com.

(Minimum Requirements to listen to broadcast: The RealPlayer software, downloadable free from http://www.real.com/products/player/index.html, or The Windows Media Player, downloadable free from www.microsoft.com and at least a 14.4Kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to [email protected])

SOURCE QIAGEN N.V.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on QIAGEN NV
04/12 QIAGEN : New research suggests potential for additional clinical utility of QIAG..
02/03 QIAGEN : Cracking the code - how RNA may hold the answer
02/01 DGAP-DD : QIAGEN N.V. english
01/27QIAGEN NV : annual earnings release
01/26 QIAGEN : QuantiFERON-TB test wins tender for testing of Republic of Korea Armed ..
01/25 QIAGEN : announces adjustment of conversion ratio under its 0.375% Senior Unsecu..
01/25 QIAGEN NV : REVERSE SPLIT: 26 of 27
01/20 QIAGEN : announces intention to adjust the conversion ratio under its 0.375% Sen..
01/18 QIAGEN : Announces Details for Completion of Approximately $250 Million Syntheti..
01/18 QIAGEN N.V. : to Report Fourth Quarter and Full Year of 2016 Results
More news
Sector news : Biotechnology & Medical Research - NEC
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
04/18DJJOHNSON & JOHNSON : Lifts Forecast on Actelion Tie-Up
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug -- Up..
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
01/17 Even A $100M Series A Can't Save The Medtech Venture Climate
01/17 Qiagen (QGEN) Presents At German Corporate Conference 2017
01/13 NEW STOCKS ON MOST ATTRACTIVE/MOST D : January 2017
01/11 Qiagen NV (QGEN) presents at 35th Annual J.P. Morgan Healthcare Conference
2016 Qiagen N.V. 2016 Q3 - Results - Earnings Call Slides